Selecta Biosciences Inc

NASDAQ:SELBUnited States

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company leverages its ImmTOR platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. It enables the re-dosing of life-saving gene therapies and restoring self-tolerance in autoimmune diseases. The ImmTOR platform reduces the formation of anti-drug antibodies (ADAs), against biologic drugs and restore self-tolerance to auto-antigens in autoimmune diseases. ImmTOR leverages nanoparticle technology to target rapamycin, an immunomodulatory drug, to antigen presenting cells to generate antigen-specific immune tolerance when combined with the antigen of interest. Its nanoparticles are designed to remain intact after injection into the body and accumulate predominantly in lymph nodes, the spleen, and the liver, where the immune response is coordinated. Its product candidate, SEL-212, which is in Phase III clinical development includes pegadricase, a pegylated uricase enzyme.

Contact Information

Headquarters

65 Grove StreetWATERTOWN, MA, United States 02472-2891

Phone

617-923-1400

Fax

617-924-3454

Executives

Independent Chairman of the Board

Carrie Cox

President, Chief Executive Officer, Director

Carsten Brunn

Chief Financial Officer

Blaine Davis

Chief Operating Officer, Senior Vice President - Research and Development

Lloyd Johnston

Chief People Officer

Kristen Baldwin